レンバチニブ

レンバチニブ 価格

メーカー	製品番号	製品説明	CAS番号	包装	価格	更新時間	購入

レンバチニブ 化学特性,用途語,生産方法

用途

レンバチニブ（Lenvatinib）は、エーザイが開発したマルチキナーゼ阻害薬であり、様々ながんの治療に用いられ得る。VEGFR2（英語版）キナーゼおよびVEGFR3（英語版）キナーゼを阻害する。 放射性ヨウ素による治療に抵抗性の甲状腺癌の治療薬として希少疾病用医薬品に指定されている。

効能

抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬

説明

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC₅₀s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC₅₀s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

特性

Class: receptor protein-tyrosine kinase
Treatment: DTC, RCC, HCC
Elimination half-life = 28 h
Protein binding = 98–99%

使用

E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.

定義

ChEBI: A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.

副作用

The most common side effects of LENVIMA (lenvatinib) in people treated for thyroid cancer include tiredness; joint and muscle pain; decreased appetite; weight loss; nausea; mouth sores; headache; vomiting; rash, redness, itching, or peeling of your skin on your hands and feet; stomach (abdomen) pain; and hoarseness.
The most common side effects of LENVIMA when given with everolimus in people treated for kidney cancer include tiredness; joint and muscle pain; decreased appetite; vomiting; nausea; mouth sores; swelling in your arms and legs; cough; stomach (abdomen) pain; trouble breathing; rash; weight loss; and bleeding.
The most common side effects of LENVIMA in people treated for liver cancer include tiredness; decreased appetite; joint and muscle pain; weight loss; stomach (abdomen) pain; rash, redness, itching, or peeling of your skin on your hands and feet; hoarseness; bleeding; change in thyroid hormone levels; nausea.

レンバチニブ 上流と下流の製品情報

原材料

準備製品

レンバチニブ 生産企業

名前	電話番号	電子メール	国籍	製品カタログ	優位度
Baoji Guokang Healthchem co.,ltd	+8615604608665 15604608665	dominicguo@gk-bio.com	CHINA	9414	58
Senova Technology Co. Ltd.	+86-0755-86703119 +8618503098836	info@senovatech.com	China	351	58
Zhengzhou Anhuida Chemical Co., Ltd	+8615903659408	admin@ahdchem.com	China	286	58
Hebei Weibang Biotechnology Co., Ltd	+8615531157085	abby@weibangbio.com	China	8807	58
Hebei Chuanghai Biotechnology Co,.LTD	+86-13131129325	sales1@chuanghaibio.com	China	5889	58
Hebei Dangtong Import and export Co LTD	+86-86-4001020630 +8619831957301	admin@hbdangtong.com	China	1000	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2472	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	10986	58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-0531-69954981 +8615666777973	dwyane.wang@boyuanpharm.com	China	211	58
Apeloa production Co.,Limited	+8619933239880	admin@apcl.com.cn	China	852	58

417716-92-8(レンバチニブ)キーワード:

---

• 417716-92-8
• 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
• E7080 (Lenvatinib)
• ER-203492-00
• 1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea
• 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445
• E70801-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea
• 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate
• LENVATINIB
• E7080; VARGATEF; E-7080; E 7080
• CS-384
• Lenvatinib base,Lenvatinib
• envatinib (E7080)
• Lenvatinib base
• Levatinib Impurity 13
• E7081）
• Lenvatini
• 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-
• Lenvatinib (free base)
• Lenvatinib USP/EP/BP
• Lenvatinib Impurity 134
• Lenvatinib Impurity 127
• Lenvatinib Impurity 128
• Lenvatinib Impurity 129
• Lenvatinib Impurity 130
• Lenvatinib Impurity 131
• Lenvatinib Impurity 132
• Lenvatinib Impurity 133
• E7080
• Lenvatinib (E7080)
• 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
• レンバチニブ
• 4-[3-クロロ-4-[(シクロプロピルアミノ)カルボニルアミノ]フェノキシ]-7-メトキシ-6-キノリンカルボキサミド
• 4-[3-クロロ-4-(3-シクロプロピルウレイド)フェノキシ]-7-メトキシキノリン-6-カルボキサミド
• 4-{3-クロロ-4-[(シクロプロピルカルバモイル)アミノ]フェノキシ}-7-メトキシキノリン-6-カルボキサミド
• E-7080
• 4-[3-クロロ-4-(3-シクロプロピルウレイド)フェノキシ]-7-メトキシキノリン-6-カルボアミド